Effects of Borneol on the Intestinal Transport and Absorption of Two P-glycoprotein Substrates in Rats

Huijuan He,Qi Shen,Jian Li 대한약학회 2011 Archives of Pharmacal Research Vol.34 No.7

As the most prevalent route of delivery, oral administration has the challenge of potentially low bioavailability in part because P-glycoprotein (P-gp) in the intestinal tract affects absorption. Therefore, absorption enhancers or P-gp inhibitors are strategies to solve this problem. The aim of the present study was to investigate the effects of borneol on transportation of colchicine and rhodamine123, two P-gp substrates, in rats. In vitro transportation was assessed with a diffusion chamber system with isolated rat intestines. Different concentrations of borneol (10, 40 and 80 μg/mL) were prepared in solutions with two P-gp substrates compared with blank solutions. The in vivo effects on colchicine were assessed by a pharmacokinetic study. Borneol enhanced the absorptive transport of two P-gp substrates, which was relevant to the concentration. A pharmacokinetic study showed that in the presence of borneol, a significant increase in C_max and AUC_(0→8)of colchicine occurred when compared to colchicine alone. The study showed that borneol affected two P-gp substrates in the intestine, possibly by inhibiting the effects of P-gp and enhancing intestinal absorption of drugs. Therefore, borneol could be developed as a P-gp inhibitor and absorptive enhancer.

Liquid phase catalytic dehydration of glycerol to acrolein over Brønsted acidic ionic liquid catalysts

Lingqin Shen,Hengbo Yin,Aili Wang,Xiufeng Lu,Changhua Zhang,Fen Chen,Yuting Wang,Huijuan Chen 한국공업화학회 2014 Journal of Industrial and Engineering Chemistry Vol.20 No.3

Liquid phase dehydration of glycerol to acrolein catalyzed by Brønsted acidic ionic liquids (BAILs) usingsemi-batch reaction technique was investigated. For the BAILs catalysts, the acrolein yields were inan order of [Bmim]H2PO4 > [Bmim]HSO4 > [BPy]HSO4 > [PSPy]HSO4 > [N2224]HSO4 > [PSPy]H2PO4> [BPy]H2PO4 > [N2224]H2PO4. When [Bmim]H2PO4 and [Bmim]HSO4 were used as the catalysts at 270℃ with the molar ratio of catalyst to glycerol of 1:100, the acrolein yields were 57.4% and 50.8%,respectively, at complete conversion of glycerol. The BAILs with [Bmim] cation and moderate acidityfavored the formation of acrolein in liquid phase glycerol dehydration.

Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer

Libing Xiang,Yunxia Tu,Tiancong He,Xuxia Shen,Ziting Li,Xiaohua Wu,Huijuan Yang 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.6

Objective: Distal pancreatectomy with splenectomy may be required for optimalcytoreductive surgery in patients with epithelial ovarian cancer (EOC) metastasized tosplenic hilum. This study evaluates the morbidity and treatment outcomes of the uncommonprocedure in the management of advanced or recurrent EOC. Methods: This study recruited 18 patients who underwent distal pancreatectomy withsplenectomy during cytoreductive surgery of EOC. Their clinicopathological characteristicsand follow-up data were retrospectively analyzed. Results: All tumors were confirmed as high-grade serous carcinomas. The mediandiameter of metastatic tumors located in splenic hilum was 3.5 cm (range, 1 to 10 cm). Optimal cytoreduction was achieved in all patients. Eight patients (44.4%) sufferedfrom postoperative complications. The morbidity associated with distal pancreatectomyand splenectomy included pancreatic leakage (22.2%), encapsulated effusion in theleft upper quadrant (11.1%), intra-abdominal infection (11.1%), pleural effusion withor without pulmonary atelectasis (11.1%), intestinal obstruction (5.6%), pneumonia(5.6%), postoperative hemorrhage (5.6%), and pancreatic pseudocyst (5.6%). Therewas no perioperative mortality. The majority of complications were treated successfullywith conservative management. During the median follow-up duration of 25 months,nine patients experienced recurrence, and three patients died of the disease. The 2-yearprogression-free survival and overall survival were 40.2% and 84.8%, respectively. Conclusion: The inclusion of distal pancreatectomy with splenectomy as part ofcytoreduction for the management of ovarian cancer was associated with high morbidity;however, the majority of complications could be managed with conservative therapy.

Mutational analysis of KRAS and its clinical implications in cervical cancer patients

Wei Jiang,Libing Xiang,Xuan Pei,Tiancong He,Xuxia Shen,Xiaohua Wu,Huijuan Yang 대한부인종양학회 2018 Journal of Gynecologic Oncology Vol.29 No.1

Objective: The predictive and prognostic role of KRAS mutations in cervical cancer remainsinconclusive. The aim of this study was to explore the clinicopathological and prognosticrelevance of KRAS mutations in invasive cervical cancers (ICC). Methods: Reverse transcription polymerase chain reaction (PCR) and Sanger sequencingwere employed to detect KRAS mutations in 876 ICC patients. Quantitative real-time PCR wasused to detect human papillomavirus (HPV) 16 and HPV 18. Results: Non-synonymous mutations of KRAS were identified in 30 (3.4%) patients. Thesemutations were more common in non-squamous cell carcinoma than in squamous cellcarcinoma (SCC) (8.2% vs. 2.2%, respectively, p<0.001) and were associated with HPV 18infection (p=0.003). The prevalence of mutations was highest (18.2%) in the uncommonhistological subtypes followed by adenocarcinoma (AC, 7.3%) and adenosquamouscarcinoma (ASC, 5.8%). During the median follow-up of 55 months, compared to patientswith wild-type KRAS, a greater percentage of patients with mutant KRAS relapsed (20.0%vs. 42.9%, respectively, p=0.007). The 3-year relapse-free survival was poorer in patientswith mutant KRAS than in patients without KRAS mutations (57.1% vs. 81.9%, respectively,p=0.001). Furthermore, the multivariate analysis showed that the presence of a KRASmutation was an independent predictor for disease recurrence (hazard ratio [HR]=2.064;95% confidence interval [CI]=1.125–3.787; p=0.019). Conclusion: KRAS mutations were predominant in non-SCCs of the cervix and wereassociated with HPV 18 infection. A combination of KRAS mutation detection andHPV genotyping would be useful in identifying patient with poor prognosis for furtherinterventions.

Inhalation of panaxadiol alleviates lung infl ammation via inhibiting TNFA/ TNFAR and IL7/IL7R signaling between macrophages and epithelial cells

Yifan Wang,Hao Wei,Zhen Song,Liqun Jiang,Mi Zhang,Xiao Lu,Wei Li,Yuqing Zhao,Lei Wu,Shuxian Li,Huijuan Shen,Qiang Shu,Yicheng Xie 고려인삼학회 2024 Journal of Ginseng Research Vol.48 No.1

Background: Lung inflammation occurs in many lung diseases, but has limited effective therapeutics. Ginseng andits derivatives have anti-inflammatory effects, but their unstable physicochemical and metabolic propertieshinder their application in the treatment. Panaxadiol (PD) is a stable saponin among ginsenosides. Inhalationadministration may solve these issues, and the specific mechanism of action needs to be studied. Methods: A mouse model of lung inflammation induced by lipopolysaccharide (LPS), an in vitro macrophageinflammation model, and a coculture model of epithelial cells and macrophages were used to study the effectsand mechanisms of inhalation delivery of PD. Pathology and molecular assessments were used to evaluate efficacy. Transcriptome sequencing was used to screen the mechanism and target. Finally, the efficacy andmechanism were verified in a human BALF cell model. Results: Inhaled PD reduced LPS-induced lung inflammation in mice in a dose-dependent manner, includinginflammatory cell infiltration, lung tissue pathology, and inflammatory factor expression. Meanwhile, the dose ofinhalation was much lower than that of intragastric administration under the same therapeutic effect, which maybe related to its higher bioavailability and superior pharmacokinetic parameters. Using transcriptome analysisand verification by a coculture model of macrophage and epithelial cells, we found that PD may act by inhibitingTNFA/TNFAR and IL7/IL7R signaling to reduce macrophage inflammatory factor-induced epithelial apoptosisand promote proliferation. Conclusion: PD inhalation alleviates lung inflammation and pathology by inhibiting TNFA/TNFAR and IL7/IL7Rsignaling between macrophages and epithelial cells. PD may be a novel drug for the clinical treatment of lunginflammation.